financetom
Business
financetom
/
Business
/
Marketing experience firm Quad Q3 net sales miss estimates on Europe operations divestiture
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Marketing experience firm Quad Q3 net sales miss estimates on Europe operations divestiture
Oct 28, 2025 1:51 PM

Overview

* Quad Q3 net sales fell 13% yr/yr, missing analyst expectations, per LSEG data

* Adjusted EPS for Q3 beats consensus, rising 19% yr/yr

* Company returned $19 mln to shareholders through dividends and share repurchases

Outlook

* Quad narrows full-year 2025 adjusted net sales decline to 3% to 5%

* Company expects 2025 adjusted EBITDA between $190 mln and $200 mln

* Quad anticipates 2025 free cash flow of $50 mln to $60 mln

Result Drivers

* EUROPEAN DIVESTITURE - Net sales decline partly due to 6% impact from divestiture of European operations

* AI INVESTMENTS - Co invests in AI-powered tools to enhance audience intelligence and drive future growth

* IN-STORE CONNECT - Co builds momentum for In-Store Connect retail media network to increase brand and product sales

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net Miss $588 mln $605.15

Sales mln (2

Analysts

)

Q3 Beat $0.31 $0.27 (2

Adjusted Analysts

EPS )

Q3 Net $10 mln

Income

Q3 $53 mln

Adjusted

EBITDA

Analyst Coverage

* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the commercial printing services peer group is "buy."

* Wall Street's median 12-month price target for Quad/Graphics Inc ( QUAD ) is $9.30, about 36.1% above its October 27 closing price of $5.94

* The stock recently traded at 6 times the next 12-month earnings vs. a P/E of 6 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Oracle's Long-Term Outlook Likely Disappointed Some Investors, UBS Says
Oracle's Long-Term Outlook Likely Disappointed Some Investors, UBS Says
Oct 17, 2025
04:12 PM EDT, 10/17/2025 (MT Newswires) -- Oracle's (ORCL) long-term outlook may have disappointed some investors, but there are reasons to own the cloud computing company's stock, UBS Securities said in a Friday note. Shares of Oracle declined 6.9% on Friday after the company said on Thursday it was aiming for earnings of $21 per share by fiscal 2030 and...
BRIEF-US FTC Says It Approves Final Divestiture Order In Synopsys And Ansys Deal
BRIEF-US FTC Says It Approves Final Divestiture Order In Synopsys And Ansys Deal
Oct 17, 2025
Oct 17 (Reuters) - * U.S. FTC SAYS IT APPROVES FINAL DIVESTITURE ORDER IN SYNOPSYS AND ANSYS DEAL * U.S. FTC SAYS IT APPROVES FINAL DIVESTITURE ORDER IN SYNOPSYS AND ANSYS DEAL Source text: https://www.ftc.gov/news-events/news/press-releases/2025/10/ftc-approves-final-divestiture-order-synopsys-ansys-deal Further company coverage: ...
Moderna Shares Fall After Early Trial Update on mRNA-4359 Cancer Vaccine Combination
Moderna Shares Fall After Early Trial Update on mRNA-4359 Cancer Vaccine Combination
Oct 17, 2025
03:32 PM EDT, 10/17/2025 (MT Newswires) -- Moderna ( MRNA ) shares were down almost 5% in recent trading on Friday after management provided an update on the company's immunotherapy pipeline and presented trial data evaluating its mRNA-4359 cancer vaccine together with pembrolizumab, according to a FactSet transcript of Moderna's ( MRNA ) oncology investor event. The company said Monday...
US FDA expands use of Amgen, AstraZeneca's drug for sinus infection
US FDA expands use of Amgen, AstraZeneca's drug for sinus infection
Oct 17, 2025
Oct 17 (Reuters) - The U.S. Food and Drug Administration has approved Amgen ( AMGN ) and AstraZeneca's ( AZN ) drug for a type of chronic sinus infection, the drugmakers said on Friday. ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved